Hydroxyapatite Nanoparticles Loaded Adriamycin Vitro Liver Cancer Research

Nanoparticles because of its unique biological effects of nano-teclm01ogy hassparked a great interest in the study. Nano-technology is to promote thedevelopment of today's medical one of the major driving forces, Nanoparticles asdrug carriers in anti-cancer research has become a hot medical research.Hydroxyapatite (HAP) nanoparticles not only have excellent biocompatibilityand tumor suppressor activity, It is also an ideal gene and drug carrier. However, itsanti-cancer drug in the carriage and treatment of cancer research is also unusual.The topics chosen homogeneous precipitation method of 1.4mg/mL HAPnanoparticles, Using oscillating so HAP nanoparticles adsorption adrimycin(ADM),Use UV spectrophotometry testing and analysis of the adsorption capacity, Theresults showed: HAP nanoparticles to 5μg/mL concentration of adriamycin largestadsorption, per gram of hydroxyapatite adsorption Adriamycin quality 284.2679mg.Using atomic force microscopy to observe the shape and extent of adsorption, theresults showed that: HAP nanoparticles adsorption 1-5μg/mL adriamycin the resultswere quite good.HAP nanoparticles loaded adriamycin (5μg/mL) and the Bel-7402 cells, L-02liver cells using optical microscopy to observe each group of the cell morphology,cell shape, and the number of adherent, The results showed HAP nanoparticlesloaded with adriamycin with the control group (5μg/mL doxorubicin), the Bel-7402cell morphology changes to the small, the normal L-02 liver cells to low toxicity.MTT assay HAP nanoparticles load adriamycin on the inhibitory rate of Bel-7402cells and normal L-02 liver cell toxic influence, The results showed: 1.4mg/mLHAP nanoparticles load 5μg/mL adriamycin can inhibit cell Bel-7402 high up to92.90±1.25%, separate application 1.4mg/mL HAP Nanoparticles on Bel-7402 cellinhibitory rate of 15.86±4.52%, 5μg/mL adriamycin on Bel-7402 cell inhibitoryrate of 81.33±1.74%. and the two drugs alone compared HAP nanoparticles load5μg/mL of adriamycin inhibition rate increased. HAP nanoparticles load 5μg/mL ofadriamycin and L-02 liver cells affect the 3rd day start, the cell toxicity obviousthan 5μg/mL adriamycin toxicity reduced cytotoxicity level, from three dropped two;5d cytotoxic levels dropped by 4 to 2.Using tetracycline and Eu-doped were labeled HAP Nanoparticles withBel-7402 cells function, using fluorescence microscopy observes the fluorescence intensity, The results showed: 2%Eu doped HAP nanoparticles the fluorescenceintensity better results. Used laser scanning confocal microscopy observation ofdynamic load HAP nanoparticles with adriamycin for. Bel-7402 cells and thedistribution process. Analysis showed 2%Eu labeled HAP nanoparticles mainlyenters the cytoplasm. HAP nanoparticles loaded adriamycin mainly enterssurrounding the nucleus and the membrane, Determined HAP nanoparticles loadedadriamycin using fluorescence of Eu-doped materials marking the bestconcentration of 2% (g/mL) and the cell-binding around time is about 2 hours,mainly enters around the cell nucleus and the cell membrane primarily, littlepartially enter the cytoplasm.In summary, HAP nanoparticles is a good drug carrier, load after adriamycinattenuated can achieve synergy effects, HAP nanoparticles loaded adriamycinfurther application of the theoretical basis, right HAP nanoparticles loadedadriamycin further research could make it may become a new generation ofanti-liver cancer treatment drug.